Intellia Therapeutics’ In Vivo CRISPR Therapy Lonvo-z Achieves 87% Attack Rate Reduction in HAE Phase 3 Trial, Initiates Rolling BLA Filing with FDA

June 28, 2026

Intellectia.AI USA

Overview

Intellia Therapeutics’ in vivo CRISPR therapy, lonvo-z, demonstrated an 87% reduction in hereditary angioedema (HAE) attack frequency in its Phase 3 HAELO trial. Following these breakthrough results, the company initiated a rolling Biologics License Application (BLA) with the FDA, targeting market launch in early next year. Sustained plasma kallikrein suppression post-single dose positions lonvo-z as a potential first one-time HAE treatment, leading to a 58% stock surge and affirming CRISPR’s transformative potential for genetic diseases.

In Depth

Key Findings

Intellia Therapeutics announced groundbreaking top-line results from its Phase 3 HAELO trial for lonvo-z, an in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE), demonstrating an 87% reduction in HAE attack frequency. Following these highly positive data, the company has initiated a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), aiming for market entry in the first half of next year. This announcement led to a significant 58% surge in the company’s stock value.

Technical / Clinical Details

Lonvo-z is engineered to utilize CRISPR technology to edit a dysfunctional gene within the patient’s body, thereby increasing the activity of C1-esterase inhibitor (C1-INH), which is deficient in HAE patients. The Phase 3 HAELO trial confirmed sustained suppression of plasma kallikrein activity after a single dose, directly leading to the dramatic reduction in HAE attack frequency. This positions lonvo-z as a potential one-time curative treatment for hereditary angioedema, offering the promise of substantially improving patients’ long-term quality of life. The therapy also demonstrated a favorable safety profile, with no serious adverse events reported.

Background & Context

Hereditary angioedema (HAE) is a rare genetic disorder characterized by severe, unpredictable swelling attacks. Existing treatments are largely limited to preventing or managing attacks, imposing a lifelong burden of medication and associated challenges on patients. The success of lonvo-z powerfully demonstrates the potential of in vivo gene editing technology to address these unmet medical needs by correcting the underlying genetic cause of the disease. This breakthrough is expected to accelerate the application of in vivo CRISPR treatments for other genetic disorders.

Strategic Significance & Outlook

The initiation of a rolling BLA submission to the FDA indicates that lonvo-z is progressing smoothly toward approval, with a rapid market launch anticipated. HAE patients may soon experience liberation from chronic disease management with the advent of this new one-time treatment option. Intellia Therapeutics’ success not only strongly validates the commercial and clinical viability of CRISPR technology but also solidifies its position as a leader in gene editing therapies, likely accelerating future pipeline development and investment in the sector globally.

Source: https://intellectia.ai/news/stock/intellia-therapeutics-advances-promising-new-therapy

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.